Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Cabaletta Bio (Nasdaq: CABA) will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 9:30 a.m. ET in New York.

Rhea-AI Summary

Cabaletta Bio (Nasdaq: CABA) will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 9:30 a.m. ET in New York. A live webcast will be available on the company website and replays will be posted for 30 days.

Argus Feb 5 session

-7.17% close to close Open Argus

Details

News Market Reaction – CABA

In the Feb 5 session, CABA declined 7.17%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -7.2% in the session following this news. A negative reaction despite a routine conf...

Analysis

The stock moved -7.2% in the session following this news. A negative reaction despite a routine conference update fits a pattern where non-clinical news, such as prior conference participation on Nov 4, 2025, coincided with a -10.3% move. The 10-Q from Nov 10, 2025 highlighted larger losses and going-concern language, which may continue to weigh on sentiment. An active but unused S-3 shelf registered on 2025-08-07 also remains a background consideration for equity holders.

Key Figures

Summit date: February 12, 2026 Presentation time: 9:30 a.m. ET Webcast replay window: 30 days

Summit date

February 12, 2026

Guggenheim Emerging Outlook: Biotech Summit 2026 fireside chat

Presentation time

9:30 a.m. ET

Scheduled start time of Guggenheim fireside chat

Webcast replay window

30 days

Replay availability on company website

Historical Context

5 past events · Latest: Jan 12

5 events

1. Jan 12

   Strategic priorities update

   24h Move

   +5.2%

   Outlined 2026 rese-cel priorities, registrational cohorts, and data-readout timelines.

2. Jan 12

   IND amendment clearance

   24h Move

   +5.2%

   FDA cleared IND amendment to use Cellares automated platforms for rese-cel manufacturing.

3. Nov 10

   Q3 2025 earnings

   24h Move

   -4.7%

   Reported larger loss, liquidity risk, and going-concern language despite pipeline progress.

4. Nov 04

   Investor conferences

   24h Move

   -10.3%

   Announced participation in multiple investor conferences with webcasted fireside chats.

5. Oct 27

   Clinical data update

   24h Move

   +13.0%

   Presented positive rese-cel clinical data across multiple RESET trials at ACR 2025.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 9:30 a.m. ET in New York, NY.

A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.

About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, please visit www.cabalettabio.com and connect with us on LinkedIn.

Contacts:

Anup Marda
Chief Financial Officer
investors@cabalettabio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Cabaletta Bio (CABA) present at the Guggenheim Emerging Outlook: Biotech Summit 2026?

Cabaletta Bio will present on February 12, 2026 at 9:30 a.m. ET. According to the company, the presentation is a fireside chat at the Guggenheim summit in New York and targets investors and industry attendees interested in autoimmune cell therapies.

How can investors watch Cabaletta Bio's (CABA) Guggenheim summit presentation?

Investors can watch via a live webcast on the company website. According to the company, the live stream is hosted on the News and Events section and a replay will be available on the site for 30 days after the event.

What topics will Cabaletta Bio (CABA) likely cover in the Guggenheim fireside chat?

The company will discuss its late-stage targeted cell therapy programs for autoimmune diseases. According to the company, the fireside chat is intended to highlight clinical progress and the company’s strategy for advancing curative therapies to patients.

Will there be a replay available for Cabaletta Bio's (CABA) Guggenheim summit presentation and for how long?

Yes, a replay will be available on the company website for 30 days following the event. According to the company, replays are posted in the News and Events section to allow investors and stakeholders to view the presentation after the live webcast.